Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%

by Zacks Equity Research

BioMarin Pharmaceutical (BMRN) shares rose nearly 9% in the last trading session, amid huge volumes.

    ISRG or ITGR: Which is a Better Medical Instrument Stock?

    by Zacks Equity Research

    Intuitive Surgical (ISRG) and Integer Holdings' (ITGR) strong fundamentals and rising share price make them close contenders.

      Here's Why You Should Sell Patterson Companies Stock Now

      by Zacks Equity Research

      A rapidly changing healthcare environment in the United States, unfavorable price movements, declining dental revenues and integration risks pose significant challenges for Patterson Companies (PDCO).

        Wright Medical Gets FDA PMA for AUGMENT Injectable, Shares Up

        by Zacks Equity Research

        Wright Medical's (WMGI) AUGMENT Injectable Bone Graft platform has same clinical indications as the company's flagship AUGMENT Bone Graft.

          PetMed (PETS) Optimistic About New Orders Amid Cost Woes

          by Zacks Equity Research

          The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.

            Medtronic ActivaProgramming Application Wins FDA Nod for DBS

            by Zacks Equity Research

            Medtronic's (MDT) ActivaProgramming Application is designed for use with Samsung Galaxy Tab S2 tablets. The therapy incorporates the inputs of more than a 100 clinicians worldwide.

              SYK or SRDX: Which is a Better Medical Product Stock?

              by Zacks Equity Research

              Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

                Idera Stock Down, Study on Dermatomyositis Candidate Fails

                by Zacks Equity Research

                Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

                  Cardinal Health to Gain From FDA Panel Vote for INCRAFT PMA

                  by Zacks Equity Research

                  Cardinal Health's (CAH) INCRAFT receives favorable recommendation from FDA for premarket approval.

                    Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                    by Zacks Equity Research

                    Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

                      Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session

                      by Zacks Equity Research

                      Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.

                        Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?

                        by Zacks Equity Research

                        IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.

                          Here's Why You Should Invest in Genomic Health (GHDX) Now

                          by Zacks Equity Research

                          Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.

                            ABMD or VAR: Which is a Better Medical Instrument Stock?

                            by Zacks Equity Research

                            It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.

                              Varian to Demonstrate Brachytherapy Solutions Portfolio

                              by Zacks Equity Research

                              Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.

                                Here's Why You Should Sell Cardinal Health (CAH) Stock Now

                                by Zacks Equity Research

                                Cardinal Health (CAH) faces sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.

                                  Company News For Jun 5, 2018

                                  by Zacks Equity Research

                                  Companies in the news are: GHDX,BAYN.DE, NKTR,DCPH

                                    Here's Why You Should Sell Accuray (ARAY) Stock Right Now

                                    by Zacks Equity Research

                                    Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).

                                      Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session

                                      by Zacks Equity Research

                                      Immunomedics (IMMU) shares rose more than 10% in the last trading session, amid huge volumes.

                                        McKesson (MCK) Acquires Medical Specialties for $800 million

                                        by Zacks Equity Research

                                        McKesson's (MCK) solid acquisition portfolio is likely to benefit the company over the long haul.

                                          Sweta Jaiswal headshot

                                          Morgan Stanley Calls Labs 'Safe Havens': Stocks to Watch

                                          by Sweta Jaiswal

                                          With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.

                                            PRA Health (PRAH) Up 0.2% in a Month Post Mixed Q1 Earnings

                                            by Zacks Equity Research

                                            PRA Health's (PRAH) shares gain from better-than-expected Q1 earnings. However, increasing labor-related costs in the Clinical Research wing is a headwind.

                                              vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9%

                                              by Zacks Equity Research

                                              vTv Therapeutics (VTVT) shares rose nearly 7% in the last trading session, amid huge volumes.

                                                Surmodics (SRDX) Gains From Consistent Efforts to Boost R&D

                                                by Zacks Equity Research

                                                Surmodics' (SRDX) consistent focus on research and development activities has been driving growth. The company is expected to make continued progress throughout the remainder of fiscal 2018.

                                                  Bio-Rad (BIO) Up 13.5% in 3 Weeks Post Solid Q1 Earnings

                                                  by Zacks Equity Research

                                                  Bio-Rad (BIO) Q1 results reflect impressive segmental sales and solid performance across all geographies.